Last reviewed · How we verify
AAPA
AAPA is a small molecule that targets the SGLT2 receptor.
AAPA is a small molecule that targets the SGLT2 receptor. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | AAPA |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
AAPA works by inhibiting the SGLT2 receptor in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |